Adaptive Biotechnologies Corporation (NASDAQ:ADPT) went down by -1.97% from its latest closing price when compared to the 1-year high value of $55.12 and move down -51.72%, while ADPT stocks collected -8.92% of loss with the last five trading sessions. Press Release reported on 07/15/20 that Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Worth an Investment?
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) 5 of the analysts out of 6 who provided ratings for Adaptive Biotechnologies Corporation stocks as a “buy” while 0 as overweight, 1 rated it as hold and 0 as sell. The average price we get from analysts is $52.25 which is $15.34 above current price. ADPT currently has a short float of 3.22% and public float of 76.08M with average trading volume of 1.18M shares.
ADPT Market Performance
ADPT stocks went down by -8.92% for the week, with the monthly drop of -20.73% and a quarterly performance of 24.85%, while its annual performance rate touched -9.65%. The simple moving average for the period of the last 20 days is -17.91% for ADPT stocks with the simple moving average of 13.43% for the last 200 days.
Analysts’ Opinion on Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Many brokerage firms have already submitted their reports for ADPT stocks, with Goldman repeating the rating for ADPT shares by setting it to “Buy”. The predicted price for ADPT socks in the upcoming period according to Goldman is $60 based on the research report published on June 3, 2020.
BTIG Research, on the other hand, stated in their research note that they expect to see ADPT stock at the price of $46. The rating they have provided for ADPT stocks is “Buy” according to the report published on July 23, 2019.
William Blair gave “Outperform” rating to ADPT stocks, setting the target price at $46 in the report published on July 22, 2019.
ADPT Stocks -14.13% Far from 50 Day Moving Average
After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, Adaptive Biotechnologies Corporation was unable to take a rebound, for now settling with -34.09% of loss for the given period.
The stock volatility was left at 4.82%, however, within the period of a single month, the volatility rate increased by 4.25%, while the shares sank at the distance of -23.01% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +2.14% upper at the present time.
In the course of the last 5 trading sessions, ADPT went down by -8.92%, which changed the moving average for the period of 200 days to the total of +22.74% of gains for the stock in comparison to the 20-day moving average settled at $43.71. In addition, Adaptive Biotechnologies Corporation saw 21.42% in overturn over the period of a single year with a tendency to cut further gains.
ADPT Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Adaptive Biotechnologies Corporation (ADPT), starting from Taylor Stacy L, who sold 2,880 shares at the price of $36.03 back on Jul 24. After this action, Rushing now owns 1,300 shares of Adaptive Biotechnologies Corporation, valued at $103,766 with the latest closing price.
BENZENO SHARON, the Chief Business Development Off of Adaptive Biotechnologies Corporation, sold 417 shares at the value of $40.00 during a trade that took place back on Jul 20, which means that BENZENO SHARON is holding 0 shares at the value of $16,680 based on the most recent closing price.
ADPT Stock Fundamentals
The current profitability levels are settled at -92.15 for the present operating margin and +65.86 for gross margin. The net margin for Adaptive Biotechnologies Corporation stands at -81.78. Total capital return value is set at -17.22, while invested capital returns managed to touch -15.28. Equity return holds the value -23.10%, with -10.00% for asset returns.
Based on Adaptive Biotechnologies Corporation (ADPT), the company’s capital structure generated 6.41 points for debt to equity in total, while total debt to capital is set at the value of 6.02.
The value for Enterprise to Sales is 17.98 with debt to enterprise value settled at 0.02. The receivables turnover for Adaptive Biotechnologies Corporation is 9.73 with the total asset turnover at the value of 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.82.